Short Interest in Appili Therapeutics Inc. (OTCMKTS:APLIF) Grows By 625.6%

Appili Therapeutics Inc. (OTCMKTS:APLIF) was the target of a large increase in short interest in November. As of November 15th, there was short interest totalling 56,600 shares, an increase of 625.6% from the October 31st total of 7,800 shares. Based on an average trading volume of 326,400 shares, the days-to-cover ratio is presently 0.2 days.

Appili Therapeutics Stock Down 11.7 %

Shares of OTCMKTS APLIF opened at $0.03 on Thursday. The stock’s fifty day simple moving average is $0.02 and its 200 day simple moving average is $0.03. The stock has a market capitalization of $3.02 million, a price-to-earnings ratio of -1.28 and a beta of -0.49. Appili Therapeutics has a 52-week low of $0.01 and a 52-week high of $0.05.

Appili Therapeutics Company Profile

Appili Therapeutics Inc, a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a taste-masked liquid oral suspension formulation of the antibiotic metronidazole to treat anaerobic bacterial, protozoal, and parasitic infections; ATI-1801, a novel topical formulation of paromomycin in Phase III clinical trials for the treatment of cutaneous leishmaniasis and disfiguring skin infections; and ATI-1701, which is a live-attenuated vaccine in preclinical trials for Francisella tularensis.